DexCom reports Q2 EPS 48c, consensus 44c

Reports Q2 revenue $1.16B, consensus $1.12B. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. “During the quarter, Dexcom (DXCM) delivered strong revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in key growth markets,” said Kevin Sayer, Dexcom’s chairman and CEO. “In the second half of 2025, we look forward to continuing our commercial momentum while advancing our product portfolio with the highly-anticipated launch of our Dexcom G7 15 Day System.”